search
CSL
Trends
- 1Italy rail strike disrupts trains from 11am to 2pmโItaly CSLE strike today: trains disrupted 11AMโ2PM; Malpensa Express affected, replacement buses available. https:// tra
A CSLE union strike in Italy is halting trains today between 11am and 2pm. Trenitalia and Trenord services are affected, including the Malpensa Express airport link, with replacement buses laid on for stranded passengers. Travellers are being warned to check schedules before heading to stations.
- 2CSL Limited share price draws investor attentionโผCSL Limited (CSL.AX) stock price, news, quote and history
Australian biotechnology company CSL Limited is being tracked by investors looking up its share price, quotes and market history on financial data platforms. The Melbourne-based blood products and vaccines maker is one of Australia's largest listed companies, and its stock is a regular focus for traders following healthcare sector moves and earnings news. No specific price movement or announcement is given.
- 3CSL may spend up to $2.2 billion on Swiss biotech dealโผCSL could spend up to $2.2b on drug deal with Swiss biotech start-up
Australian biotech giant CSL is reported to be weighing a deal worth up to $2.2 billion with a Swiss biotech start-up, according to the Australian Financial Review. The arrangement would centre on rights to a drug candidate, adding to CSL's pipeline as it looks for new growth areas beyond its established plasma-based therapies.
- 4CSL and Alentis sign $1.6bn deal for rare kidney and liver diseasesโCSL and Alentis strike $1.6bn collab for rare kidney and liver diseases
Australian biotech giant CSL and Swiss-based Alentis Therapeutics have announced a collaboration worth up to $1.6 billion to develop treatments for rare kidney and liver diseases. The partnership will combine Alentis's antibody-drug conjugate platform with CSL's development and commercialisation resources, aiming to bring new therapies to patients with limited treatment options.
- 5CSL signs drug deal with Swiss biotech giant on rare diseaseโASX CSL: CSL signs drug deal with Swiss biotech giant to fight rare disease
Australian biotech CSL has signed a deal with a major Swiss pharmaceutical company to develop a treatment for a rare disease, according to the Australian Financial Review. The agreement, reported for ASX-listed CSL, marks another step in the company's push to expand its pipeline beyond its core plasma and vaccine businesses. Details of the partner, the disease and financial terms were not disclosed in the initial report.
- 6
Australian biotech CSL has signed a drug development agreement with a Swiss biotech company to develop a treatment for a rare disease. The deal pairs CSL's global plasma and therapeutics scale with the Swiss firm's early-stage pipeline, and marks another step in CSL's push to expand beyond its core blood products business into rare and serious conditions.
- 7CSL and Alentis Sign $1.6 Billion Rare Disease Drug DealโCSL, Alentis Partner on $1.6B Rare Disease Drug Deal | Finance News
Australian biotech giant CSL and Swiss clinical-stage company Alentis Therapeutics have struck a partnership worth up to $1.6 billion to develop a treatment for a rare disease. Under the deal, CSL will pay upfront and milestone-based fees to gain rights to Alentis's drug candidate, adding to growing industry interest in niche rare-disease therapies.